Multicentre Perspective Non-interventional Study of Survival Benefits of iCAGES-guided Therapy in Contrast to Standard Therapy or IHC-guided Therapy for Advanced Cancers
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
This study prospectively evaluates whether the use of iCAGES (integrated CAncer GEnome Score) tool in guiding the treatment of advanced cancers is superior to current standard care or IHC-guided therapy in progress free survival (PFS),overall survival (OS),and improvement of life quality.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:
• Pathological and clinical diagnosis of recurrence / metastatic lung cancer or other advanced cancers.
• There are PACS images available at the Second Affiliated Hospital of Guangzhou Medical University and the collaborated Hospitals.
• The patient is informed consent and signed a written consent.
Locations
Other Locations
China
The Second Affiliated Hospital of Guangzhou Medical University
RECRUITING
Guangzhou
Contact Information
Primary
Zhenfeng Zhang, MD,PhD
zhangzhf@gzhmu.edu.cn
+86-020-34153532
Backup
Deji Chen, MD,PhD
chendeji2003@163.com
+86-020-34153532
Time Frame
Start Date: 2017-07-01
Estimated Completion Date: 2039-07-01
Participants
Target number of participants: 250
Treatments
Study group (A group)
In this group, we perform whole exome or genome sequencing of tumor sample in compared to blood sample, screen tumor-related special mutations by using biomedical informatics analysis procedure and utilized the iCAGES system to rank the most appropriate drugs available and then manually examine this list to select the best therapeutic strategy for the patient based on availability of drug and expert knowledge. The PFS, OS, and quality of life (QOL) will be recorded and compared with that from standard care.
Control group (B group)
In this group, patients with advanced cancers (matched with Group A) will be treated under the guidance of NCCN, without performing iCAGES analysis.
Control group (C group)
In this group, patients with advanced cancers (matched with Group A) will be treated with appropriate targeted drugs according to IHC detection of more than 20 protein molecules with blank tissue slides from the cancer.
Related Therapeutic Areas
Sponsors
Leads: Second Affiliated Hospital of Guangzhou Medical University
Collaborators: The First Affiliated Hospital of Guangzhou Medical University, Sun Yat-sen University